Intervacc has now completed the negotiations with 3P Biopharmaceuticals in Pamplona, Spain and signed the agreement for contract manufacturing of Strangvac®. The agreement means that the production and documentation of the important validation batches required for registration of the new recombinant vaccine against equine strangles have been secured. 3P Biopharmaceuticals is a strategic partner to Intervacc and this manufacturing agreement fulfills the intentions from previously announced letter of intent and agreements for the first milestones. The agreement now signed by the companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.